scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22
scPharmaceuticals Inc. (Nasdaq: SCPH) announced a conference call scheduled for March 22, 2023, at 4:30 p.m. ET to discuss its fourth quarter 2022 financial results and provide a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
scPharmaceuticals Inc. (Nasdaq: SCPH) announced a conference call scheduled for March 22, 2023, at 4:30 p.m. ET to discuss its fourth quarter 2022 financial results and provide a business update. The call will be accessible via telephone and an audio webcast. The company focuses on developing innovative pharmaceuticals aimed at reducing healthcare costs and improving patient outcomes, specifically targeting outpatient care for acute conditions such as heart failure and infectious diseases.
Positive
- Focus on developing innovative products to reduce healthcare costs.
- Targeting outpatient care for acute conditions like heart failure.
Negative
- None.
Details
News Market Reaction – SCPH
The recorded move for SCPH in the trading session of this news was -2.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to host conference call and webcast at 4:30 p.m. ET
BURLINGTON, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 22, 2023, to discuss the financial results for the fourth quarter 2022 and provide a business update.
Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13736270.
To access the new Call me™ feature, which avoids having to wait for an operator, click here.
The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com
Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7578
pkelleher@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.